

## R&D Pipeline Phase III & Registration

### Phase III

Name	Description	Indication
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Prurigo Nodularis
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Bullous Pemphigoid
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Chronic Spontaneous Urticaria
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Chronic Obstructive Pulmonary Disease
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Chronic Inducible Cold Urticaria
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Chronic Rhinosinusitis without Nasal Polyps
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Allergic Fungal Rhinosinusitis
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Chronic Pruritus of Unknown Origin
<b>itepekimab</b> <sup>A</sup>	Anti-IL-33 mAb	Chronic Obstructive Pulmonary Disease
<b>Libtayo</b> <sup>®A</sup>	Anti-PD-1 mAb	Adjuvant CSCC
<b>Sarclisa</b> <sup>®</sup>	Anti-CD38 mAb + combinations	1L Newly Diag. MM Tt (IMROZ)
<b>Sarclisa</b> <sup>®</sup>	Anti-CD38 mAb + combinations	1L Newly Diag. MM Te (GMMG)
<b>Sarclisa</b> <sup>®</sup>	Anti-CD38 mAb + combinations	Smoldering MM (ITHACA)
<b>amcenestrant</b>	SERD + palbociclib	1L Metastatic breast cancer
<b>amcenestrant</b>	SERD	Adjuvant breast cancer
<b>tusamitamab ravtansine</b>	Anti-CEACAM5 ADC	2/3L NSCLC
<b>tolebrutinib</b>	BTK inhibitor	Relapsing Multiple Sclerosis
<b>tolebrutinib</b>	BTK inhibitor	Primary Progressive MS
<b>tolebrutinib</b>	BTK inhibitor	Secondary Progressive MS
<b>tolebrutinib</b>	BTK inhibitor	Myasthenia Gravis
<b>Nexviazyme</b> <sup>®</sup>	Enzyme Replacement Therapy (GAA)	Pompe Disease - Infantile Onset
<b>venglustat</b>	Oral GCS inhibitor	GM2 Gangliosidosis
<b>fitusiran</b>	RNAi targeting anti-thrombin	Hemophilia A and B
<b>fitusiran</b>	RNAi targeting anti-thrombin	Hemophilia A and B pediatric
<b>rilzabrutinib</b>	BTK inhibitor	Immune Thrombocytopenia
<b>efanesoctocog alfa</b> <sup>®</sup>	rFVIII Fc - vWF - XTEN	Hemophilia A
<b>MenQuadfi</b> <sup>®</sup>	Meningococcal (A,C,Y,W) conjugate vaccine	Meningitis 6w+ (US / EU)
<b>VerorabVax</b> <sup>®</sup>	Purified vero rabies vaccine	Rabies

### Registration

Name	Description	Indication
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Atopic Dermatitis 6 months – 5 years old
<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Eosinophilic Esophagitis
<b>Libtayo</b> <sup>®A</sup>	Anti-PD-1 mAb	2L Cervical Cancer
<b>Libtayo</b> <sup>®A</sup>	Anti-PD-1 mAb + chemotherapy	1L NSCLC
<b>SP0253</b> <sup>D</sup>	Recombinant baculovirus Vaccine	COVID-19
<b>nirsevimab</b> <sup>C</sup>	Monoclonal Antibody	Respiratory Syncytial Virus (RSV)

- Immuno-inflammation
- Oncology
- Neurology
- Rare Diseases
- Rare Blood Disorders
- Vaccines

## R&D Pipeline – Phase II

### Phase II

	Name	Description	Indication
R	<b>Kevzara</b> <sup>®A</sup>	Anti-IL-6 mAb	Polyarticular Juvenile Idiopathic Arthritis
R	<b>Kevzara</b> <sup>®A</sup>	Anti-IL-6 mAb	Systemic Juvenile Arthritis
	<b>Dupixent</b> <sup>®A</sup>	Anti-IL-4/IL-13 mAb	Peanut Allergy
	<b>amitelimab</b> <sup>1</sup>	Anti-OX40L mAb	Atopic Dermatitis
	<b>rilzabrutinib</b>	BTK inhibitor	IgG4-related disease
	<b>rilzabrutinib</b>	BTK inhibitor	Atopic Dermatitis
	<b>rilzabrutinib</b>	BTK inhibitor	Asthma
	<b>rilzabrutinib</b>	BTK inhibitor	Chronic Spontaneous Urticaria
	<b>eclitasertib</b> <sup>E,2</sup>	RIPK1 inhibitor	Cutaneous Lupus Erythematosus
	<b>SAR441344</b> <sup>F</sup>	Anti-CD40L mAb	Sjogren's Syndrome
	<b>SAR441344</b> <sup>F</sup>	Anti-CD40L mAb	Systemic Lupus Erythematosus
	<b>SAR444727</b>	BTK inhibitor (topical)	Atopic Dermatitis
R	<b>Sarclisa</b> <sup>®</sup>	Anti-CD38 mAb	1-2L AML / ALL pediatrics
	<b>Sarclisa</b> <sup>®</sup>	Anti-CD38 mAb + combinations	Relapsed, Refractory Multiple Myeloma
	<b>alomofilimab</b> <sup>3</sup>	Anti-ICOS mAb	Solid tumors
	<b>tusamitamab ravtansine</b>	Anti-CEACAM5 ADC + ramucirumab	2/3L NSCLC
	<b>tusamitamab ravtansine</b>	Anti-CEACAM5 ADC	Exploratory Solid tumors
	<b>tusamitamab ravtansine</b>	Anti-CEACAM5 ADC + pembrolizumab	1L NSCLC
	<b>tusamitamab ravtansine</b>	Anti-CEACAM5 ADC + ramucirumab	Gastric cancer
	<b>SAR444245</b> <sup>4</sup>	Non-alpha IL-2 + cemiplimab	Skin cancers
	<b>SAR444245</b> <sup>4</sup>	Non-alpha IL-2 + combinations	Gastrointestinal cancer
	<b>SAR444245</b> <sup>4</sup>	Non-alpha IL-2 + combinations	NSCLC / Mesothelioma
	<b>SAR444245</b> <sup>4</sup>	Non-alpha IL-2 + combinations	Head & Neck tumors
	<b>SAR444245</b> <sup>4</sup>	Non-alpha IL-2 + combinations	Lymphoma
	<b>SAR442720</b> <sup>G</sup>	SHP2 inhibitor + KRAS inhibitor	2L NSCLC

	Name	Description	Indication
	<b>SAR445088</b> <sup>5</sup>	Complement C1s inhibitor	CIDP
	<b>SAR441344</b> <sup>F</sup>	Anti-CD40L mAb	Multiple Sclerosis
	<b>SAR339375</b>	miRNA-21	Alport Syndrome
	<b>venglustat</b>	Oral GCS inhibitor	Fabry Disease
	<b>venglustat</b>	Oral GCS inhibitor	Gaucher Disease Type 3
	<b>Sarclisa</b> <sup>®</sup>	Anti-CD38 mAb	Warm Autoimmune Hemolytic Anemia
	<b>rilzabrutinib</b>	BTK inhibitor	Warm Autoimmune Hemolytic Anemia
	<b>SAR445088</b> <sup>5</sup>	Complement C1s inhibitor	Cold Agglutinin Disease
	<b>Fluzone</b> <sup>® HD (SP0178)</sup>	Inactivated influenza Vaccine (IIV)	Pediatric Flu
	<b>SP0218</b>	Vero cell Vaccine	Yellow fever
	<b>SP0202</b> <sup>H</sup>	Next Generation Conjugate Vaccine	Pneumococcal
	<b>SP0125</b>	Live Attenuated Virus Vaccine	Respiratory syncytial virus (toddler)
	<b>SP0230</b>	Multicomponent Vaccine	Meningitis B

- Immuno-inflammation
- Oncology
- Neurology
- Rare Diseases
- Rare Blood Disorders
- Vaccines
- R Registrational Study (other than Phase 3)

# R&D Pipeline – Phase I

## Phase I

Name	Description	Indication
<b>SAR441566</b>	Oral TNF inhibitor	Inflammatory indications
<b>SAR444656</b> <sup>1</sup>	IRAK4 degrader	Atopic Dermatitis
<b>SAR444336</b>	Pegylated IL-2	Inflammatory Indication
<b>SAR443726</b>	Anti-IL-13/OX40L Nanobody® VHH	Atopic Dermatitis
<b>SAR442970</b>	Anti-TNFα/OX40L Nanobody® VHH	Inflammatory Indication
<b>SAR443765</b>	Anti-IL-13/TSLP Nanobody® VHH	Inflammatory Indication
<b>SAR442999</b>	Anti-TNFα/IL23A Nanobody® VHH	Inflammatory Indication
<b>SAR441000</b> <sup>3</sup>	Cytokine mRNA	Solid tumors
<b>SAR442257</b>	Anti-CD38xCD28xCD3 trispecific mAb	MM / N-H Lymphoma
<b>SAR442720</b> <sup>6</sup>	SHP2 inhibitor + pembrolizumab	1L NSCLC
<b>SAR444881</b> <sup>k</sup>	Anti-ILT2 mAb	Solid tumors
<b>SAR445419</b> <sup>2</sup>	NK-cell-based immunotherapy	Acute Myeloid Leukemia
<b>SAR443216</b>	Anti-CD3xCD28xHER2 trispecific mAb	Gastric cancer
<b>SAR445710</b> <sup>3</sup>	Anti-PD-L1/IL-15 fusion protein	Solid tumors
<b>SAR443579</b> <sup>l</sup>	Anti-NKp46/CD123 bispecific mAb	Acute Myeloid Leukemia
<b>SAR443820</b> <sup>E,4</sup>	RIPK1 inhibitor	Amyotrophic Lateral Sclerosis
<b>SAR442501</b>	Anti-FGFR3 mAb	Achondroplasia
<b>SAR443809</b>	Anti-Factor Bb mAb	Rare renal diseases
<b>SP0273</b>	mRNA Vaccine	Influenza

- Immuno-inflammation
- Oncology
- Neurology
- Rare Diseases
- Rare Blood Disorders
- Vaccines

As of March 31, 2022. For collaborations see slide 52. For abbreviations see slide 53.  
1. Also known as KT474. 2. Formerly known as KDS1001. 3. Formerly known as KD033. 4. Also known as DNL788.